Hydroxyl-platelet-activating factor exists in blood of healthy volunteers and periodontal patients. by Antonopoulou, Smaragdi et al.
PERIODONTAL diseases are localized chronic inflamma-
tory conditions of the gingival and underlying bone
and connective tissue. Platelet-activating factor (PAF),
a potent inflammatory phospholipid mediator that
has been previously detected in elevated levels in
inflamed gingival tissues, in gingival crevicular fluid
and in saliva, is implicated in periodontal disease.
Our results from previous studies showed that the
biologically active phospholipid detected in gingival
crevicular fluid is a hydroxyl-PAF analogue. In this
study, hydroxyl-PAF analogue was detected for the
first time in human blood derived from patients with
chronic periodontitis as well as from periodontally
healthy volunteers. The hydroxyl-PAF analogue was
purified by high-performance liquid chromatogra-
phy, detected by biological assays and identified by
electrospray analysis. In addition, the quantitative
determination of PAF and hydroxyl-PAF analogue
(expressed as PAF-like activity) showed a statistically
significant increase in the ratio of hydroxyl-PAF
analogue levels to PAF levels in periodontal patients,
suggesting that this bioactive lipid may play a role in
oral inflammation.
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Introduction
Periodontal disease is a chronic disorder that occurs
in susceptible individuals and is initiated when
microorganisms of dental plaque (i.e. Porphyromo-
nas gingivalis, Actinobacillus actinomycetemcomi-
tans, Treponema dentocola) colonize the gingival
sulcus, and thereafter the periodontal pocket. The
inflammatory response by the host results in destruc-
tion of periodontal tissues and alveolar bone loss.
1
Several reviews have summarized the role of
activated inflammatory cells (e.g. polymorphonuc-
lears, macrophages and lymphocytes) when chal-
lenged by bacterial lipopolysaccharide, as a key
regulator of periodontal disease expression. These
cells produce and secrete proinflammatory mediators
such as interleukin-1b and tumour necrosis factor-g
that induce and enhance the production of prosta-
glandin E2 and matrix metallo-proteinases. These
molecules mediate destruction of the extracellular
matrix of periodontal tissues and resorption of the
alveolar bone.
2,3
Platelet-activating factor (PAF), a potent inflamma-
tory phospholipid mediator that has been previously
detected in elevated levels in inflamed gingival
tissues and gingival crevicular fluid (GCF), is impli-
cated in periodontal disease.
4,5
Our results from previous studies obtained from
chemical and enzymatic treatments, and biological
assays as well as from electrospray analysis showed
that the biologically active phospholipid detected in
GCF is not a typical PAF molecule (1-O-alkyl-2-
acetyl-sn-glycero-3-phosphocholine),
6 but a hydrox-
yl-PAF analogue.
7
Studies have also revealed that PAF is actually a
family of structurally related acetylated phospholi-
pids, which possesses potent inflammatory activities.
8
It has also been reported that salivary PAF levels are
increased in periodontitis, most probably originated
from the crevicular space and derived from inflam-
matory cells within the gingival and/or periodontal
tissues.
9,10
In addition, recent cross-sectional and prospective
epidemiological studies have demonstrated an asso-
ciation between periodontal disease and athero-
sclerosis and human coronary heart disease.
11 13
Periodontitis and cardiovascular disease share risk
factors including tobacco smoking, male gender,
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221race, age, education, poverty index, diabetes, sys-
temic hypertension and hypercholesterolaemia.
These commonalities suggest that periodontal dis-
ease and heart disease may also have many patho-
genetic mechanisms in common. It is possible that
infection and chronic inflammatory condition such as
periodontitis may contribute to the pathogenesis of
atherosclerosis. The chronicity of periodontal disease
provides a rich source of bacterial and host response
products for a long period of time. Two main
processes may provide an etiological link between
these two diseases: the bacterial lipopolysaccharide
and the monocyte-related responses.
2,14
It should be noted that PAF and the other unique
acetylated phospholipids are produced by a variety
of cells that participate in the development of
inflammatory reaction such as monocytes/macro-
phages, polymorphonuclear neutrophils and plate-
lets.
8,15 PAF, and mostly PAF-like oxidized
phospholipids, are implicated in atherosclerosis and
cardiovascular diseases.
16 20 These findings suggest
that inflammatory mediators such as the hydroxyl-
PAF analogue, which was identified in GCF, may also
be present in blood.
The purpose of this study was to detect and
identify the hydroxyl-PAF analogue in human blood
and to have a first approach on evaluation of the




In this study, five patients with chronic adult period-
ontitis and five periodontally healthy volunteers
participated. Both groups consisted of males, aged
32 /41 years; none of them had received any period-
ontal treatment or antibiotic therapy during the past 6
months. The characterization of periodontitis was
based on the measurements of clinical parameters,




All reagents and chemicals were analytical grade
supplied by Merck (Darmstadt, Germany). High-
performance liquid chromatography (HPLC) solvents
were from Rathburn (Walkerburn, UK) Lipid stan-
dards, bovine serum albumin (BSA) and thrombin
were obtained from Sigma (St Louis, MO, USA). Semi-
synthetic PAF (80% C-16PAF and 20% C-18PAF) was
synthesized in our laboratory as previously de-
scribed.
6 PAF-acetylhydrolase was from human
serum, purified according to the method of Stafforini
et al.
21 Silicic acid, 35-70 mesh, ASTM 7733 (Merck),
was used for column chromatography.
Instrumentation
The separation of lipids was performed at room
temperature on a HP HPLC Series 1100 liquid
chromatography model (Hewlett Packard, Wald-
bronn, German) equipped with a 100 ml loop
Rheodyne (7725 i) loop valve injector, a degasser
G1322A, a quat gradient pump G1311A and a HP UV
spectrophotometer G1314A as a detection system.
The spectrophotometer was connected to a Hewlett-
Packard model HP-3395 integrator-plotter. PAF-in-
duced aggregation was measured in a Chrono-Log
(Havertown, PA, USA) aggregometer (model 400-VS)
coupled to a Chrono-Log recorder. The electrospray
ionization (ESI) mass spectrometry experiments were
performed on an API 100 Perkin Elmer SCIEX single
quadrupole mass spectrometer. Samples were dis-
solved in a small volume of HPLC-grade methanol/
water (70:30, v/v), 0.01 M in ammonium acetate.
Electrospray samples are typically introduced into the
mass analyser at a rate of 4.0 ml/min. The positive and
negative ions, generated by charged droplet evapora-
tion, enter the analyser through an interface plate and
a 100 mm orifice, while the de-clustering potential is
maintained between 60 and 100 V to control the
collisional energy of the ions entering the mass
analyser. The emitter voltage is typically maintained
at 4000 V. The electrospray ionization tandem mass
spectrometry (MS/MS) experiments were performed
on a Finnigan LCQ quadrupole ion trap mass
spectrometer. Electrospray samples were typically
introduced into the mass analyser at a rate of 4.0
ml/min. The positive and negative ions, generated by
charged droplet evaporation, entered the analyser
through a heated capillary plate. The emitter voltage
was typically maintained at 4000 V.
PAF and hydroxyl-PAF analogue isolation and
purification
The isolation and purification of PAF and hydroxyl-
PAF analogue was performed according to
the method of Demopoulos et al.
22 Briefly, 20 ml
of blood were collected from each human subject
and, immediately after collection, were poured
into 80 ml of absolute ethanol and centrifuged at
1000 /g for 20 min. The supernatant and the pellet
were extracted according to the Bligh /Dyer
method,
23 and the phased chloroforms were mixed.
The extracts were purified on silicic acid column
chromatography that is eluted with 45 ml of metha-
nol/water (1:1.5, v/v), followed by 50 ml of metha-
nol/water (2:1, v/v). The initial 45 ml (containing the
bulk of proteinaceous and other non-lipid impurities)
were discarded while the PAF containing eluents
S. Antonopoulou et al.
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column, Sphereclone 5u NH2 250 /4.6 mm I.D.,
from Phenomenex (Hurdsfield, UK), was used.
24 The
solvent system consisted of an isocratic elution with
100% solvent A (acetonitrile/methanol, 70:30, v/v) for
35 min followed by a linear gradient to 100% solvent
B (methanol) in 5 min, a hold for 5 min in 100%
solvent B followed by a linear gradient to 100%
solvent C (water) in 5 min, and finally a hold in 100%
solvent C for 10 min. The eluted substances were
detected using ultraviolet detection at 208 nm.
Biological assays
Semi-synthetic PAF and the examined samples were
dissolved in 2.5 mg BSA/ml of saline. Thrombin was
dissolved in saline. The PAF and the hydroxyl-PAF
activity were estimated by measuring the biological
activity towards washed rabbit platelets, comparing
the PAF-induced aggregation with known concentra-
tions of semi-synthetic PAF. Experiments with specific
inhibitor BN 52021, 0.1 mM (0.3% dimethylsulph-
oxide in water), were also performed. This inhibitor
was added to the aggregometer cuvette containing
washed rabbit platelets 1 min prior to the addition of
the examined sample. This experiment was carried
out according to Lazanas et al.
25 In desensitization
and cross-desensitization experiments, platelets were
desensitized by the addition of the test lipid to the
platelet suspension at a concentration that caused
reversible aggregation. Second stimulation with PAF
or thrombin was performed immediately after com-
plete disaggregation.
Treatment with acetylhydrolase
The effect of PAF acetylhydrolase of human serum,
an enzyme specific to short or intermediate length sn-
2 chains, on the ability of fractions to induce platelet
aggregation was examined. Briefly, Tris buffer (50
FIG. 1. (A) Representative HPLC separation of polar lipids from periodontal patients blood on a normal-phase NH2 column. The
solvent system consisted of an isocratic elution with 100% solvent A (acetonitrile/methanol, 70:30) for 35 min followed by a
linear gradient to 100% solvent B (methanol) for 5 min, a hold for 5 min in 100% solvent B followed by a linear gradient to
100% solvent C (water) for 5 min, and ﬁnally a hold in 100% solvent C for 10 min. The eluted substances were detected using
ultraviolet detection at 208 nm. (B) Representative HPLC separation of polar lipids from healthy volunteers blood. HPLC
conditions were the same as already described. PE, phosphatidylethanolamine; PC, phosphatidylcholine; SM, sphingomyelin;
LPC, lysophosphatidylcholine; OH-PAF, hydroxyl-PAF; a.u.f.s., absorption units full scale.
Hydroxyl-PAF in blood
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examined sample in BSA at 2.5 mg/ml of saline were
added to a pre-warmed (378C) test tube. The enzy-
matic system was incubated at 378C and, at different
time intervals, aliquots were taken to test their ability
to induce washed rabbit platelet aggregation.
Mild alkaline hydrolysis and re-acetylation
An amount of the examined samples was subjected to
mild alkaline hydrolysis and re-acetylation, while
another amount of these lipids was only subjected
to acetylation. The biological activities of the lipids
derived from the aforementioned chemical reactions
were then tested on washed rabbit platelets. These




Data are expressed as mean values9 /standard devia-
tions. For the statistical comparison of values the t-
test was used.
Results and discussion
The HPLC purification step from the PAF isolation
procedure
24 has been modified in the present study,
in order to achieve separation of hydroxyl-PAF
analogue from PAF itself. The purified and identified
hydroxyl-PAF analogue from GCF
7 was used as
standard and it was eluted under the HPLC conditions
described in Methods. Subsequently, fractions of 1 ml
were manually collected and tested for their ability to
induce washed rabbit platelet aggregation. The same
procedure was performed for semi-synthetic PAF.
The results showed that PAF and the hydroxyl-PAF
analogue were completely separated under the
aforementioned HPLC conditions with retention
times of 30 /34 min and 38 /42 min, respectively.
Blood samples from patients and from period-
ontally healthy volunteers were separately purified
under the same HPLC conditions, and fractions of 1
ml were manually collected from 25 to 48 min.
Representative chromatographs along with the elu-
tion times of standard lipids are shown in Fig. 1A,B.
The PAF and the PAF-like activity were estimated in
each HPLC fraction by bioassay studies based on
washed rabbit platelets. PAF derived from patients’
blood and the one from healthy volunteers was
detected from 30 to 33 min and from 29 to 32 min,
respectively, while hydroxyl-PAF analogue was de-
tected from 37 to 39 min and from 36 to 39 min,
respectively (Fig. 1). Fractions from 37 to 39 min were
pooled together, representing hydroxyl-PAF analo-
gue from periodontal patients. The same procedure
was followed for fractions from 36 to 39 min
representing hydroxyl-PAF analogue from healthy
volunteers.
These hydroxyl-PAF analogues desensitized plate-
lets against PAF and themselves, but not against
thrombin (Fig. 2). Furthermore, the aggregation
induced by these molecules was inhibited by BN
52021, a specific PAF-receptor antagonist. As we have
previously reported,
7 the concentration of the hy-
droxyl-PAF analogue, which induces 50% of the
maximum aggregation (EC50), based on phosphorus
determination, was in the order of 0.1 mM (final
concentration), while its threshold concentration
allowing platelet aggregation was in the order of
0.03 mM (final concentration), being less active than
PAF, which induces aggregation with a EC50 value in
the order of 0.1 nM (final concentration). Incubation
of the hydroxyl-PAF analogues with human serum
acetylhydrolase resulted in their time-dependent
inactivation, with a rate identical to that of PAF,
suggesting the presence of an acetyl group at the sn-
2 position of a glyceryl backbone. Mild alkaline
hydrolysis rendered the hydroxyl-PAF analogues
FIG. 2. (A) Reversible washed rabbit platelet aggregation
curves induced by semi-synthetic PAF and by the hydroxyl-
PAF analogue isolated from blood, and the irreversible
washed rabbit platelet aggregation curve induced by throm-
bin. (B) Desensitization experiments with washed rabbit
platelets: (1) PAF against hydroxyl-PAF analogue; (2) hydro-
xyl-PAF analogue against PAF; (3) PAF against thrombin; (4)
hydroxyl-PAF analogue against thrombin.
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chloroform-soluble fractions, resulting from the ear-
lier hydrolysis, increased their biological activity.
Acetylation of the initial hydroxyl-PAF analogues
resulted in an increase of their biological activity,
identical to that observed after the re-acetylation of
the chloroform-soluble fractions.
Even though the retention times of the hydroxyl-
PAF analogues as well as their biological character-
istics were almost identical to that of the hydroxyl-
PAF analogue from GCF,
7 these lipids isolated from
blood samples were consequently subjected to ESI
analysis, in order to confirm that all these inflamma-
tory molecules share the same structure.
The positive ESI spectra of the fractions were







  ions, at mass-to-charge ratio (m/z)
704, 726 and 1407, respectively. The ions at m/z 184,
147, 125 and 104, which correspond to fragments of
the phosphocholine moiety, were also present.
The ESI-MS/MS spectrum of the fragment ion at m/
z 704 is represented in Fig. 4. The abundant ion at m/
z 184 is corresponded to the phosphocholine moiety.
The positive fragment ion at m/z 686 may correspond
to the loss of H2O, while the other fragments at m/z
645 and 521 should correspond to the loss of
[N(CH3)3] and of the polar choline phosphate head
group as neutral fragment 183 Da from the molecule.
Identical fragmentations were observed at the ESI-
MS/MS spectrum of the positive ion at m/z 726 (Fig.
5), with fragment ions at m/z 667 [M
 Na-N(CH3)3]
 ,
at m/z 542 [M
 Na-183]
  and at m/z 184. These
FIG. 4. Positive ion electrospray MS/MS spectrum of the ion at m/z 704.
FIG. 3. Positive ion electrospray mass spectrum of the HPLC fraction of the hydroxyl-PAF analogue isolated from blood.
Hydroxyl-PAF in blood
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sodiated phosphatidylcholine molecules [26] and for
lysoglycerophosphocholine lipids [27]. In addition a
positive ion at m/z 502 was present that should
correspond to the loss of the acetyl group [M
 Na-
183-42]
  from the sn-2 position of the glyceryl-
backbone.
The ESI-MS/MS positive spectrum of the fragment




FIG. 6. Positive ion electrospray MS/MS spectrum of the ion at m/z 1407.
FIG. 5. Positive ion electrospray MS/MS spectrum of the ion at m/z 726.
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active lipid, present in periodontal patients blood as
well as in healthy individuals blood, is indeed a
hydroxyl-PAF analogue identical to that isolated from
GCF.
7
The quantitative determination of PAF and hydrox-
yl-PAF analogue levels, based on PAF-like activity,
showed that in patients with periodontitis PAF levels
as well as hydroxyl-PAF analogue levels were not
different from those of healthy individuals (Table 1).
A statistically significant increase was detected in the
ratio of hydroxyl-PAF analogue levels to PAF levels in
periodontal patients, suggesting that this bioactive
lipid may play a role in oral inflammation.
In conclusion, the existence of an endogenous
hydroxyl-PAF analogue in human blood is reported
for the first time. This biologically active lipid is
identical to that isolated from GCF samples. Although
the precise source as well as the possible pathophy-
siological role of hydroxyl-PAF analogue remains to
be established, it seems that the infected period-
ontium can be a source of potentially inflammatory
mediators. On the contrary, since PAF and PAF-like
oxidized phospholipids are implicated in athero-
sclerosis and cardiovascular diseases; the hydroxyl-
PAF analogue could be a link between periodontal
disease and atherosclerosis. However, much remains
to be understood about the exact mechanism through
which PAF-like molecules exert their action.
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Table 1. PAF and hydroxyl-PAF analogue levels in blood collected from ﬁve periodontally healthy volunteers as well as from
ﬁve patients with chronic adult periodontitis
Healthy individuals Patients p values
PAF levels (moles/ml of blood) 3.439 /0.86 /10
 14 2.479 /0.93 /10
 14  /0.05
Hydroxyl-PAF levels (moles/ml of blood) 0.819 /0.18 /10
 14 0.749 /0.29 /10
 14  /0.05
Hydroxyl-PAF levels to PAF levels 23.669 /1.49 30.09 /1.80 B/0.05
Hydroxyl-PAF in blood
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